Antibody

JOINN has established in vivo detection technology of antibody drugs in line with international standards, and has the facility scale and technical capability to carry out in vivo drug concentration analysis of multiple biotech drugs simultaneously.

From 2017 to now, more than half of antibody drugs accepted by China CDE were evaluated by JOINN, which include monoclonal antibodies, bispecific antibodies, and ADCs. Among the monoclonal antibody targets accepted by CDE, the hottest target was TNF-α, accounting for 22%. The highly evaluated targets include VEGF, PD1/PDL1, HER2, EGFR, IL17, PCSK9, CD20, etc. Currently, ADC drug targets under development almost cover all proven drug targets, except for antibody drug targets already on the market, such as Her2, EGFR, CD19, CD22, CD70 and many other novel targets.